MDXG 10-Q Quarterly Report March 31, 2013 | Alphaminr
ALPHAMINR

MDXG 10-Q Quarter ended March 31, 2013

Balance Sheet
Cash Flow
Income Statement
MIMEDX GROUP, INC.
10-Ks and 10-Qs
10-Q
Quarter ended Sept. 30, 2025
10-Q
Quarter ended June 30, 2025
10-Q
Quarter ended March 31, 2025
10-K
Fiscal year ended Dec. 31, 2024
10-Q
Quarter ended Sept. 30, 2024
10-Q
Quarter ended June 30, 2024
10-Q
Quarter ended March 31, 2024
10-K
Fiscal year ended Dec. 31, 2023
10-Q
Quarter ended Sept. 30, 2023
10-Q
Quarter ended June 30, 2023
10-Q
Quarter ended March 31, 2023
10-K
Fiscal year ended Dec. 31, 2022
10-Q
Quarter ended Sept. 30, 2022
10-Q
Quarter ended June 30, 2022
10-Q
Quarter ended March 31, 2022
10-K
Fiscal year ended Dec. 31, 2021
10-Q
Quarter ended Sept. 30, 2021
10-Q
Quarter ended June 30, 2021
10-Q
Quarter ended March 31, 2021
10-K
Fiscal year ended Dec. 31, 2020
10-Q
Quarter ended Sept. 30, 2020
10-Q
Quarter ended June 30, 2020
10-Q
Quarter ended March 31, 2020
10-K
Fiscal year ended Dec. 31, 2019
10-Q
Quarter ended Sept. 30, 2019
10-Q
Quarter ended June 30, 2019
10-Q
Quarter ended March 31, 2019
10-K
Fiscal year ended Dec. 31, 2018
10-Q
Quarter ended Sept. 30, 2017
10-Q
Quarter ended June 30, 2017
10-Q
Quarter ended March 31, 2017
10-K
Fiscal year ended Dec. 31, 2016
10-Q
Quarter ended Sept. 30, 2016
10-Q
Quarter ended June 30, 2016
10-Q
Quarter ended March 31, 2016
10-K
Fiscal year ended Dec. 31, 2015
10-Q
Quarter ended Sept. 30, 2015
10-Q
Quarter ended June 30, 2015
10-Q
Quarter ended March 31, 2015
10-K
Fiscal year ended Dec. 31, 2014
10-Q
Quarter ended Sept. 30, 2014
10-Q
Quarter ended June 30, 2014
10-Q
Quarter ended March 31, 2014
10-K
Fiscal year ended Dec. 31, 2013
10-Q
Quarter ended Sept. 30, 2013
10-Q
Quarter ended June 30, 2013
10-Q
Quarter ended March 31, 2013
10-K
Fiscal year ended Dec. 31, 2012
10-Q
Quarter ended Sept. 30, 2012
10-Q
Quarter ended June 30, 2012
10-Q
Quarter ended March 31, 2012
10-K
Fiscal year ended Dec. 31, 2011
10-Q
Quarter ended Sept. 30, 2011
10-Q
Quarter ended June 30, 2011
10-Q
Quarter ended March 31, 2011
10-K
Fiscal year ended Dec. 31, 2010
10-Q
Quarter ended Sept. 30, 2010
10-Q
Quarter ended June 30, 2010
10-Q
Quarter ended March 31, 2010
PROXIES
DEF 14A
Filed on June 18, 2025
DEF 14A
Filed on April 30, 2025
DEF 14A
Filed on June 5, 2024
DEF 14A
Filed on April 23, 2024
DEF 14A
Filed on May 15, 2023
DEF 14A
Filed on June 7, 2022
DEF 14A
Filed on April 26, 2022
DEF 14A
Filed on Oct. 15, 2020
DEF 14A
Filed on Aug. 3, 2020
DEF 14A
Filed on April 13, 2017
DEF 14A
Filed on April 12, 2016
DEF 14A
Filed on April 3, 2015
DEF 14A
Filed on April 4, 2013
DEF 14A
Filed on Oct. 4, 2012
DEF 14A
Filed on Nov. 23, 2011
DEF 14A
Filed on April 16, 2010
10-Q 1 form10q.htm MIMEDX GROUP INC 10-Q 3-31-2013 form10q.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended March 31, 2013

OR

o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____________________to______________________

Commission file number 0-52491

MIMEDX GROUP, INC.
(Exact name of registrant as specified in its charter)

Florida
26-2792552
(State or other jurisdiction of incorporation)
(I.R.S. Employer Identification Number)

60 Chastain Center Blvd., Suite 60
Kennesaw, GA
30144
(Address of principal executive offices)
(Zip Code)

(678) 384-6720
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o
Accelerated filer x
Non-accelerated filer o
(Do not check if a smaller reporting company)
Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes o No x
As of April 19, 2013, there were 95,944,519 shares outstanding of the registrant’s common stock.
MIMEDX GROUP, INC.
Part I     FINANCIAL INFORMATION
Item 1
Condensed Consolidated Financial Statements
3
4
5
6
7
Item 2
16
Item 3
20
Item 4
21
Part II     OTHER INFORMATION
Item 1
21
Item 1A
21
Item 2
21
Item 3
22
Item 4
22
Item 5
22
Item 6
22
23

Forward-Looking Statements
This Form 10-Q and certain information incorporated herein by reference contain forward-looking statements and information within the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. This information includes assumptions made by, and information currently available to management, including statements regarding future economic performance and financial condition, liquidity and capital resources, acceptance of the Company’s products by the market, and management’s plans and objectives. In addition, certain statements included in this and our future filings with the Securities and Exchange Commission (“SEC”), in press releases, and in oral and written statements made by us or with our approval, which are not statements of historical fact, are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “seeks,” “plan,” “project,” “continue,” “predict,” “will,” “should,” and other words or expressions of similar meaning are intended by us to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are found at various places throughout this report and in the documents incorporated herein by reference. These statements are based on our current expectations about future events or results and information that is currently available to us, involve assumptions, risks, and uncertainties, and speak only as of the date on which such statements are made.
All forward-looking statements are subject to the risks and uncertainties inherent in predicting the future.  Our actual results may differ materially from those projected, stated or implied in these forward-looking statements as a result of many factors, including our critical accounting policies and risks and uncertainties related to, but not limited to, overall industry environment, delay in the introduction of products, regulatory delays, negative clinical results, and our financial condition.   These and other risks and uncertainties are described in more detail in our most recent Annual Report on Form 10-K, as well as other reports that we file with the SEC.
Forward-looking statements speak only as of the date they are made and should not be relied upon as representing our views as of any subsequent date.  We undertake no obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by applicable laws, and you are urged to review and consider disclosures that we make in this and other reports that we file with the SEC that discuss factors germane to our business.
Part I - FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements

MIMEDX GROUP, INC. AND SUBSIDIARIES
ASSETS

March 31,
December 31,
2013
2012
(unaudited)
Current assets:
Cash and cash equivalents
$ 5,725,107 $ 6,754,485
Accounts receivable, net
9,821,503 7,653,561
Inventory, net
3,956,339 3,022,784
Prepaid expenses and other current assets
1,186,417 657,961
Total current assets
20,689,366 18,088,791
Property and equipment, net of accumulated depreciation of $2,378,590 and $2,279,840, respectively
1,153,667 1,071,625
Goodwill
4,040,443 4,040,443
Intangible assets, net of accumulated amortization of $5,111,352 and $4,848,756, respectively
11,649,153 11,911,749
Deposits and other long term assets
319,545 70,000
Total assets
$ 37,852,174 $ 35,182,608
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$ 1,056,707 $ 1,251,684
Accrued compensation
3,518,769 2,753,237
Accrued expenses
1,227,485 990,697
Other current liabilities
167,600 75,154
Total current liabilities
5,970,561 5,070,772
Earn-out liability payable in MiMedx common stock
- 5,792,330
Convertible Senior Secured Promissory Notes, net
- 4,012,442
Other Liabilities
288,438 299,762
Total liabilities
6,258,999 15,175,306
Commitments and contingencies (Note 13)
Stockholders' equity:
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding
- -
Common stock; $.001 par value; 130,000,000 shares authorized; 95,825,353 issued and 95,775,353 outstanding for 2013 and 88,423,169 issued and 88,373,169 outstanding for 2012
95,824 88,423
Additional paid-in capital
102,826,481 89,627,601
Treasury stock (50,000 shares at cost)
(25,000 ) (25,000 )
Accumulated deficit
(71,304,130 ) (69,683,722 )
Total stockholders' equity
31,593,175 20,007,302
Total liabilities and stockholders' equity
$ 37,852,174 $ 35,182,608

See notes to condensed consolidated financial statements
MIMEDX GROUP, INC. AND SUBSIDIARIES
(unaudited)

Three Months Ended March 31,
2013
2012
Revenues:
Net sales
$ 11,556,493 $ 3,705,808
Cost of sales
1,905,020 958,855
Gross margin
9,651,473 2,746,953
Operating expenses:
Research and development expenses
1,246,757 407,072
Selling, general and administrative expenses
8,369,010 2,637,269
Amortization of intangible assets
262,596 333,977
Operating income (loss)
(226,890 ) (631,365 )
Other income (expense), net
Amortization of debt discount
(1,328,439 ) (310,477 )
Interest expense, net
(14,804 ) (151,810 )
Income (loss) before income tax provision
(1,570,133 ) (1,093,652 )
Income tax provision
(50,275 ) -
Net Income (loss)
$ (1,620,408 ) $ (1,093,652 )
Net income (loss) per common share - basic and diluted
$ (0.02 ) $ (0.01 )
Weighted average shares outstanding - basic and diluted
93,128,466 74,872,122

See notes to condensed consolidated financial statements
MIMEDX GROUP, INC. AND SUBSIDIARIES
For the Three Months Ended March 31, 2013
(unaudited)

Convertible
Preferred Stock
Additional
Series A
Common Stock
Paid-in
Treasury
Accumulated
Shares
Amount
Shares
Amount
Capital
Stock
Deficit
Total
Balance December 31, 2012
- $ - 88,423,169 $ 88,423 $ 89,627,601 $ (25,000 ) $ (69,683,722 ) $ 20,007,302
Share-based compensation  expense
- - - - 984,792 - - 984,792
Exercise of stock options
- - 170,099 170 232,361 - - 232,531
Exercise of warrants
- - 785,166 785 923,839 - - 924,624
Common stock issued for 5% convertible note
- - 5,272,004 5,272 5,266,732 - - 5,272,004
Common stock issued for earn-out liability
- - 1,174,915 1,174 5,791,156 - - 5,792,330
Net income (loss )
- - - - - - (1,620,408 ) (1,620,408 )
Balance March 31, 2013
- $ - 95,825,353 $ 95,824 $ 102,826,481 $ (25,000 ) $ (71,304,130 ) $ 31,593,175

See notes to condensed consolidated financial statements
MIMEDX GROUP, INC. AND SUBSIDIARIES
(unaudited)

Three Months Ended March 31,
2013
2012
Cash flows from operating activities:
Net income (loss)
$ (1,620,408 ) $ (1,093,652 )
Adjustments to reconcile net income (loss) to net cash from operating activities:
Depreciation
98,751 110,388
Amortization of intangible assets
262,596 333,977
Amortization of debt discount and deferred financing costs
1,328,439 310,477
Share-based compensation
984,792 500,985
Increase (decrease) in cash resulting from changes in:
Accounts receivable
(2,167,942 ) (961,633 )
Inventory
(933,555 ) (82,914 )
Prepaid expenses
(555,692 ) (212,831 )
Other assets
(249,545 ) -
Accounts payable
(194,977 ) (232,054 )
Accrued compensation
765,532 103,616
Accrued expenses
236,788 (224,282 )
Accrued interest
(41,641 ) 150,013
Other liabilities
(11,324 ) 9,971
Net cash flows from operating activities
(2,098,186 ) (1,287,939 )
Cash  flows from investing activities:
Purchases of equipment
(73,534 ) (46,794 )
Net cash flows from investing activities
(73,534 ) (46,794 )
Cash flows from financing activities:
Proceeds from exercise of warrants
924,624 322,673
Proceeds from exercise of stock options
232,531 171,000
Repayment of convertible debt related to acquisition
- (250,000 )
Payments under capital lease obligations
(14,813 ) -
Net cash flows from financing activities
1,142,342 243,673
Net change in cash
(1,029,378 ) (1,091,060 )
Cash and cash equivalents, beginning of period
6,754,485 4,112,326
Cash and cash equivalents, end of period
$ 5,725,107 $ 3,021,266

See notes to condensed consolidated financial statements
MIMEDX GROUP, INC.
FOR THE THREE MONTHS ENDED MARCH 31, 2013 and 2012
1.
Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulations S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs’”) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the three months ended March 31, 2013 and 2012, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2012, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.
You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2012 included in our Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (“SEC”) on March 15, 2013.
The Company operates in one business segment, Biomaterials, which includes the design, manufacture, and marketing of products and amnion tissue processing for a variety of surgical applications using the Company’s proprietary biomaterials—CollaFix™, HydroFix®, EpiFix® and AmnioFix®.

2.
Significant Accounting Policies
Please see Note 2 to our Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2012, for a description of all significant accounting policies.
Reclassifications
Certain items previously reported in combined financial statement captions have been reclassified to conform to the current financial statement presentation. These reclassifications did not affect total assets, total liabilities, and stockholders’ equity.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customer’s current creditworthiness, customer concentration, age of accounts receivable balance and general economic conditions that may affect the customer’s ability to pay.  The Company has $76,000 and $49,000 in the allowance for doubtful accounts as of March 31, 2013 and December 31, 2012, respectively.  Actual customer collections could differ from estimates.  The approximate provision during the three months ended March 31, 2013 was $27,000 compared to $4,000 for the three months ended March 31, 2012. There were no write – offs during the reporting periods.
Inventories

Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory.
Revenue Recognition
The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilized distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all revenue recognition criteria have been met. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.  The Company recorded approximately $190,000 and $39,000 for net sales returns provisions for the three months ended March 31, 2013 and 2012, respectively, and there were approximately $156,000 and $0 of charges against the provision during the three months ended March 31, 2013 and 2012, respectively.
Recent Accounting Pronouncements
The Company considers the applicability and impact of all ASUs. For the three months ended March 31, 2013 and through the date of this report, all ASUs issued, effective and not yet effective, were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial position or results of operations.
3.
Liquidity and Management’s Plans
As of March 31, 2013, the Company had approximately $5,725,000 of cash and cash equivalents.  The Company reported total current assets of approximately $20,689,000 and current liabilities of approximately $5,971,000 as of March 31, 2013.  The Company believes that its anticipated cash from operating and financing activities and existing cash and cash equivalents will enable the Company to meet its operational liquidity needs, fund its planned investing activities for the next twelve months.

4.
Inventories
Inventories consisted of the following items as of March 31, 2013 and December 31, 2012:

March 31, 2013
December 31, 2012
Raw materials
$ 279,442 $ 233,747
Work in process
$ 2,630,888 $ 1,598,537
Finished goods
$ 1,230,124 $ 1,349,121
4,140,454 3,181,405
Reserve for obsolescence
$ (184,115 ) $ (158,621 )
Inventory, net
$ 3,956,339 $ 3,022,784

5.
Property and Equipment
Property and equipment consist of the following as of March 31, 2013 and December 31, 2012:
March 31, 2013
December 31, 2012
Leasehold improvements
$ 1,129,488 $ 1,022,230
Lab and clean room equipment
1,887,645 1,887,645
Furniture and office equipment
433,314 431,563
Construction in progress
81,810 10,027
3,532,257 3,351,465
Less accumulated depreciation
(2,378,590 ) (2,279,840 )
$ 1,153,667 $ 1,071,625
6.
Intangible Assets and Royalty Agreement
Intangible assets activity is summarized as follows:
March 31, 2013
December 31, 2012
Weighted
Average
Gross
Net
Gross
Net
Amortization
Carrying
Accumulated
Carrying
Carrying
Impairment
Accumulated
Carrying
Lives
Value
Amortization
Value
Value
Adjustment
Amortization
Value
Intangible assets subject to amortization:
License-Shriners Hsp for Children & USF Research (a)
10 years
$ 996,000 $ (612,533 ) $ 383,467 $ 996,000 $ — $ (587,633 ) $ 408,367
License - SaluMedica LLC Spine Repair (b)
10 years
1,547,324 (1,547,324 ) - 2,399,000 (851,676 ) (1,547,324 ) -
License - Polyvinyl Alcohol Cryogel (c)
10 years
1,720,181 (1,255,692 ) 464,489 2,667,000 (946,819 ) (1,223,561 ) 496,620
Customer Relationships (d)
14 years
3,520,000 (565,714 ) 2,954,286 3,520,000 (502,857 ) 3,017,143
Supplier Relationships (d)
14 years
241,000 (38,732 ) 202,268 241,000 (34,428 ) 206,572
Patents & Know-How (d)
14 years
5,530,000 (888,750 ) 4,641,250 5,530,000 (790,000 ) 4,740,000
Micronized Processing Know-How (d)
14 years
2,160,000 (192,857 ) 1,967,143 2,160,000 (154,286 ) 2,005,714
Licenses/Permits (d)
3 years
13,000 (9,750 ) 3,250 13,000 (8,667 ) 4,333
15,727,505 (5,111,352 ) 10,616,153 17,526,000 (1,798,495 ) (4,848,756 ) 10,878,749
Intangible assets not subject to amortization:
Trade Names/Trademarks (d)
indefinite
1,008,000 — 1,008,000 1,008,000 — — 1,008,000
In-process Research & Development-Other (d)
indefinite
25,000 — 25,000 25,000 — — 25,000
$ 16,760,505 $ (5,111,352 ) $ 11,649,153 $ 18,559,000 $ (1,798,495 ) $ (4,848,756 ) $ 11,911,749

(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.  The acquisition price of this license was a one-time fee of $100,000 and 1,120,000 shares of common stock valued at $896,000 (based upon the estimated fair value of the common stock on the transaction date).  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products.

(b)
License from SaluMedica, LLC (SaluMedica) for the use of certain developed technologies related to spine repair.  This license was acquired through the acquisition of SpineMedica Corp.  In September 2012, the cost of this license was deemed to be impaired and reduced to its fair value.

(c)
On March 31, 2008, the Company entered into a license agreement for the use of certain developed technologies related to surgical sheets made of polyvinyl alcohol hydrogel.  The acquisition price of the asset was 400,000 shares of common stock valued at $2,596,000 (based upon the closing price of the common stock on the transaction date).  The agreement also provides for the issuance of an additional 600,000 shares upon the Company meeting certain milestones related to future sales.  On December 31, 2009, the Company completed the sale of its first commercial product and met its first milestone under this agreement.  As a result, the Company issued an additional 100,000 shares of common stock to the licensor valued at $71,000.  In September 2012, the cost of the license was deemed to be impaired and reduced to its fair value.  At March 31, 2013 and December 31, 2012, there are no additional amounts accrued for this obligation due to its contingent nature.
(d)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for customer and supplier relationships, patents and know-how, licenses/permits, trade names and trademarks and in-process research and development.
Future Amortization Expense
Expected future amortization of intangible assets is as follows:

Estimated
Amortization
Year ending  December 31,
Expense
2013
$ 787,785
2014
1,046,047
2015
1,023,992
2016
976,998
2017
886,801
Thereafter
5,894,530
$ 10,616,153

(a)
Estimated amortization expense for the year ending December 31, 2013 includes only amortization to be recorded after March 31, 2013.

7 .
Long-Term Debt

The following table summarizes our long-term debt:

March 31,
December 31,
2013
2012
$5M Convertible Senior Secured Promissory Notes including interest at 5% per annum payable quarterly through December 31, 2013, and an additional one time 5% interest charge payable on January 15, 2013 if not repaid by December 31, 2012, collateralized by a first priority lien shared equally with holder of the Convertible Line of Credit with Related Party in all of the patents and intellectual property owned by the Company subordinated to the Convertible Debt related to acquisition for Surgical Biologics intellectual property until repaid. (a)
$ - $ 5,313,645
Total debt
$ - $ 5,313,645
Less unamortized debt discount
- (1,301,203
Less current portion
- -
Long-term portion
$ - $ 4,012,442

(a) Investors received First Contingent Warrants (25% of amount invested) and Second Contingent Warrants (25% of amount invested) at an exercise price of $.01 per share. On December 31, 2011, a total of 1,250,000 First Contingent Warrants were vested. In July 2012, a total of 1,250,000 Second Contingent Warrants were voided due to the Company's share price trading at or above $1.75 for ten consecutive trading days. The additional interest resulting from the beneficial conversion feature, inclusive of the First Contingent Warrants, totaled $2,278,052 which was recorded as a debt discount and was amortized to interest expense using the effective interest rate over the life of the note.
Senior Secured Promissory Notes
From December 27 to December 31, 2011, the Company sold 5% Convertible Senior Secured Promissory Notes (the “Notes”) to individual accredited investors for aggregate proceeds of $5,000,000.  The aggregate proceeds included $500,000 of Notes sold to the Company’s Chairman of the Board and CEO.  In total, the principal of the Notes is convertible into up to 5,000,000 shares of common stock of the Company (“Common Stock”) plus accrued but unpaid interest at $1.00 per share at any time upon the election of the holder of the note.
As of December 31, 2012, the Company had not repaid the Notes in full and as a result requires the Company to pay each lender an additional interest payment in the amount of five percent (5%) of the aggregate outstanding principal amount of such lender’s Notes as of December 31, 2012.  The additional interest was accrued on a monthly basis during the year.
In conjunction with the sale of the Notes, the Company incurred a placement fee of $32,800 and issued 42,400 common stock warrants to the placement agents at an exercise price of $1.09 per share.  The warrants expire in five years.  The fair value of the warrants was determined to be approximately $15,000 using the Black-Scholes-Merton valuation technique.  The total direct costs of approximately $47,800 are recorded as deferred financing costs and are being amortized over the term of the Notes using the effective interest method.  Further, the placement agent warrants are classified in stockholders’ equity because they achieved all of the requisite conditions for equity classification in accordance with GAAP.
During the months of January and February 2013, all holders of the Notes converted their interest in this obligation to shares of MiMedx common stock.  The total amount of debt plus accrued interest that was exchanged was approximately $5,272,000.  In conjunction with this exchange approximately 5,272,000 shares of the Company’s common stock were issued in full satisfaction of this obligation.  Included in this total are 532,260 shares representing the Chief Executive Officer’s conversion of his Note.  This also resulted in the acceleration of amortization of debt discount and total interest expense of approximately $1,328,000 during the quarter ended March 31, 2013.
8.
Net Income (loss) Per Share
Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net loss per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, warrants and convertible debt using the treasury stock method.  For all periods presented, diluted net loss per share is the same as basic net loss per share, as the inclusion of equivalent shares from outstanding common stock options, warrants and convertible debt would be anti-dilutive.
The following table sets forth the computation of basic and diluted net loss per share:

Three months ended March 31,
2013
2012
Net income (loss)
$ (1,620,408 ) $ (1,093,652 )
Denominator for basic earnings per share - weighted average shares
93,128,466 74,872,122
Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (a)
— —
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
93,128,466 74,872,122
Income (loss) per common share - basic and diluted
$ (0.02 ) $ (0.01 )

(a) Securities outstanding that were excluded from the computation, prior to the use of the treasury stock method, because they would have been anti-dilutive are as follows:

Three months ended March 31,
2013
2012
Outstanding Stock Options
16,022,703 12,517,000
Outstanding Warrants
2,344,002 7,891,567
Convertible Debt, promissory notes
— 5,131,018
Convertible Line of Credit with Related Party
— 1,358,931
Convertible Debt, Acquisition
— 1,059,836
18,366,705 27,958,352
9.
Equity
Stock Incentive Plans
The Company has three share-based compensation plans: the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “2006 Plan”), the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”) which provide for the granting of qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the 2006 Plan to make future grants. The number of assumed options under the Assumed 2005 Plan and Assumed 2007 Plan outstanding at March 31, 2013 totaled 375,000.  On March 6, 2013, the Board of Directors approved 6,000,000 additional shares to be made available under the 2006 Plan, bringing the maximum number of shares of common stock which can be issued under the 2006 Plan to 22,500,000 at March 31, 2013, subject to the ratification and approval by the Company’s stockholders.
Activity with respect to the stock options is summarized as follows:
Number of
Shares
Weighted-
Average
Exercise
Price
Weighted-
Average
Remaining
Contractual
Term
(in years)
Aggregate
Intrinsic
Value
Outstanding at January 1, 2013
13,614,135 $ 1.42
Granted
2,645,000 $ 5.04
Exercised
(170,099 ) $ 1.37
Unvested options forfeited
(59,667 ) $ 2.32
Vested options expired
(6,666 ) $ 1.15
Outstanding at March 31, 2013
16,022,703 $ 2.02
Vested at March 31, 2013
6,853,995 $ 1.11 6.7 $ 27,258,080
Vested or expected to vest at March 31, 2013
15,641,584 $ 1.98 8.1 $ 48,645,480
(a)
Includes forfeiture adjusted unvested shares.
The intrinsic value of the options exercised during the three months ended March 31, 2013, was approximately $613,000.
Following is a summary of stock options outstanding and exercisable at March 31, 2013:

Options Outstanding
Options Exercisable
Range of Exercise Prices
Number outstanding
Weighted-
Average
Remaining
Contractual
Term
(in years)
Weighted-
Average
Exercise
Price
Number Exercisable
Weighted-
Average
Exercise Price
$ 0.50 - $0.76 2,319,500 5.2 $ 0.67 2,319,500 $ 0.67
$ 0.87 - $1.35 7,002,003 8.3 1.19 3,092,797 1.19
$ 1.40 - $2.29 1,851,700 6.7 1.63 1,441,698 1.66
$ 2.33 - $3.75 2,179,500 9.5 2.75 ─ ─
$ 3.85 - $5.80 2,670,000 9.9 5.03 ─ ─
16,022,703 8.1 $ 2.02 6,853,995 $ 1.11
Total unrecognized compensation expense related to granted stock options at March 31, 2013, was approximately $12,961,000 and is expected to be recognized over a weighted-average period of 2.6 years.
The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.
The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:

Three months ended March 31,
2013
2012
Expected volatility
64.3 % 58.3 %
Expected life (in years)
6 6
Expected dividend yield
— —
Risk-free interest rate
0.98%-1.86 % 0.88 %
The weighted-average grant date fair value for options granted during the three months ended March 31, 2013 was approximately $2.94
During the first quarter of 2013, the Company granted 250,000 shares of restricted stock with a weighted-average grant date fair value of $5.07 which vest over a three year period.  As of March 31, 2013, there was approximately $1,262,000 of total unrecognized stock-based compensation related to time-based, nonvested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.93 years.
For the three months ended March 31, 2013 and 2012, the Company recognized stock-based compensation as follows:
Three Months Ended March 31,
2013
2012
Cost of products sold
$ 50,162 $ 24,010
Research and development
75,978 71,520
Selling, general and administrative
858,652 405,455
$ 984,792 $ 500,985
Warrants
The Company grants common stock warrants in connection with equity share purchases by investors as an additional incentive for providing long term equity capital to the Company and as additional compensation to consultants and advisors.  The warrants are granted at negotiated prices in connection with the equity share purchases and at the market price of the common stock in other instances.  The warrants have been issued for terms of five years.
Following is a summary of the warrant activity for the three months ended March 31, 2013:

Number of
Warrants
Weighted-
Average
Exercise
Price per
Warrant
Warrants outstanding at January 1, 2013
3,129,168 $ 1.04
Warrants exercised:
Contingent warrants related to private placement of common stock
(62,500 ) 0.01
Callable warrants
(266,666 ) 1.50
Other
(456,000 ) 1.15
Warrants outstanding at March 31, 2013
2,344,002 $ 1.00
Warrants may be exercised in whole or in part by:
·
notice given by the holder accompanied by payment of an amount equal to the warrant exercise price multiplied by the number of warrant shares being purchased; or
·
election by the holder to exchange the warrant (or portion thereof) for that number of shares equal to the product of (a) the number of shares issuable upon exercise of the warrant (or portion) and (b) a fraction, (x) the numerator of which is the market price of the shares at the time of exercise minus the warrant exercise price per share at the time of exercise and (y) the denominator of which is the market price per share at the time of exercise.
These warrants are not mandatorily redeemable, and do not obligate the Company to repurchase its equity shares by transferring assets or issue a variable number of shares.
The warrants require that the Company deliver shares as part of a physical settlement or a net-share settlement, at the option of the holder, and do not provide for a net-cash settlement.
All of our warrants are classified as equity as of March 31, 2013 and December 31, 2012.
10.
Income taxes
The Company has incurred net losses since its inception, and therefore, no current income tax liabilities have been incurred for the periods presented.  However, the Company does have franchise tax obligations in certain states.  This expense and related liability is included in the accompanying financial statements as income tax provision and accounts payable, respectively.  The amount of federal operating loss carryforwards was approximately $43,100,000 at March 31, 2013.  A valuation allowance is recorded to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that a portion or none of the deferred tax assets will be realized.  After consideration of all the evidence, including reversal of deferred tax liabilities, future taxable income and other factors, management has determined that a full valuation allowance is necessary as of March 31, 2013.  Additionally, the Company has various tax credit carryforwards of approximately $1,400,000 as of March 31, 2013.
11.
Supplemental disclosure of cash flow and non-cash investing and financing activities:

Three Months Ended
March 31,
2013
2012
Cash paid for interest
$ 3,688 $ 2,435
Income taxes paid
7,275 -
Purchases of property, plant and equipment financed via capital leases
107,259 -
Stock issuance in lieu of Director's fees
- 184,653
Deferred financing costs
27,236 4,747
Beneficial conversion related to line of credit with related party
- 514,456
Stock issuance in connection of Earn Out Liability
5,792,330 -
Stock issuance in exchange for convertible debt
5,272,004 -
Cashless exercise of warrants
- 136
12.
Leased Equipment under Capital Leases
March 31, 2013
December 31, 2012
Leased equipment under capital leases
Leased equipment under capital leases
$ 175,793 $ 84,650
Less:  payments under capital lease obligations
14,813 16,116
Leased equipment under capital leases, net
$ 160,980 $ 68,534
The Company has capital leases with interest rates ranging from 6.78% to 12.34% and maturity dates from June 2015 through January 2018.
13.
Contractual Commitments
In addition to the Capital Leases noted above, the Company has entered into operating lease agreements for facility space and equipment. In addition, the Company has minimum royalty payments due in conjunction with one of its licenses.  The estimated annual lease and royalty expense are as follows:
12-month period ended March 31
2014
$ 295,553
2015
142,767
2016
50,000
2017
50,000
Thereafter
387,500
$ 925,820
14.
Subsequent Events
As a condition of the lease for new office space that will commence on May 1, 2013 the Company was obligated to post an additional security deposit of approximately $250,000 which it deposited on April 5, 2013 increasing the total amount deposited to approximately $500,000.

Overview
MiMedx Group, Inc. ("MiMedx Group") is an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane.
" Innovations in Regenerative Biomaterials " is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant.
Recent Events
During the months of January and February 2013, all holders of the Convertible Senior Secured Promissory Notes converted their interest in this obligation to shares of MiMedx common stock.  The number of shares of common stock issued as a result of these transactions totaled approximately 5,272,000.  In connection with this conversion, the Company expensed, during the quarter, approximately $1,328,000 of debt discount and deferred financing costs.  Included in this total are approximately 532,000 shares representing the Chief Executive Officer’s conversion of his Note.

On January 31, 2013, the Company entered into a lease agreement (the “Lease”) under which the Company will lease approximately 80,000 square feet of office, laboratory and warehouse space in Marietta, Georgia.  The building will become the Company’s new corporate headquarters.  The initial term of the lease is sixty nine (69) months commencing on
May 1, 2013.  Base rental payments over the term of the lease total approximately $6,700,000.  Under the Lease, the Company has posted a security deposit of approximately $500,000 of which $250,000 was paid after the end of the first quarter 2013.

In March of 2013, the Company issued approximately 1,175,000 shares of Common Stock in final settlement of the earn-out liability connected with the 2011 acquisition of Surgical Biologics.

During the quarter, the Company was granted one international patent for the hydrogel technology, one US patent for the collagen technology, and four US patents for the amnion technology.  Additionally, we filed sixteen applications during the most recent quarter, including five non-provisional applications for the collagen technology and eleven non-provisional applications for the amnion technology.
Results of Operations Comparison for the Three Months Ended March 31, 2013 to the Three Months Ended March 31, 2012

Revenue
Total revenue increased approximately $7,851,000 to $11,557,000 for the three months ended March 31, 2013, as compared to $3,706,000 for the three months ended March 31, 2012.  The increase in revenue as compared to the prior year is due primarily to increased sales of our amniotic membrane tissue products, EpiFix ® and AmnioFix ® .  The Company experienced an approximate increase of $2,551,000 or 127% in demand in the Surgical and Sports Medicine market. This growth over prior year was driven by increased use of our AmnioFix injectable products as well as additional surgical applications where the anti-scarring properties of the tissue were deemed to be beneficial. The growth in Wound Care market revenue of approximately $5,184,000 or 444% as compared to $1,169,000 in the prior year driven by the addition of a direct sales force starting in the third quarter of 2012 and continuing into the first quarter of 2013 focusing on Government accounts. The sales executives hired have extensive experience in the wound care sector and maintain direct relationships with the physicians. Sales to Government accounts are sold through a distributor who handles all of the contracting matters including invoicing and collection.  This distributor is also a service disabled veteran owned small business.  The Other markets category which includes our Ophthalmic and Dental tissue based products which are sold on an OEM basis as well as our HydroFix® medical device product sold through distributors increased approximately $115,000 or22% as compared to prior year.
Tissue Processing Costs and Cost of Products Sold
Cost of products sold as a percentage of revenue improved to 16.5% from 25.9% as compared to prior year.  The improvement was due primarily to the increase in direct sales revenue, improved product mix and higher production rates that absorb a greater percentage of fixed manufacturing costs. Personnel costs represent approximately $1,127,000 or 59.2% of total manufacturing, quality assurance and recovery spending for the three months ended year March 31, 2013 .
Research and Development Expenses
Our research and development expenses (“R&D expenses”) increased approximately $840,000 or 206.3% to $1,247,000 during the three months ended March 31, 2013, compared to approximately $407,000 in the prior year.  The increase is primarily related to increased investments in clinical trials and patent related costs.  Approximately $233,000, or 18.7%, of R&D expenses for the three months ended March 31, 2013 were attributable to personnel costs, compared to approximately $136,000 or 33.4% for the three months ended March 31, 2012.
Our research and development expenses consist primarily of internal personnel costs, clinical trials, fees paid to external consultants, and supplies and instruments used in our laboratories.
Selling, General and Administrative Expenses
Selling, General and Administrative expenses for the three months ended March 31, 2013, increased approximately $5,732,000 to $8,369,000 compared to $2,637,000 for the three months ended March 31, 2012.  Selling expense increases were driven by costs associated with building our direct sales organization for Government accounts and to a lesser degree our commercial direct sales organization as well as increased commissions due to higher sales volume. Increased spending on support costs related to medical reimbursement including our reimbursement hotline, our information technology infrastructure to help manage the growth of the business, increased share based compensation expense and a provision for anticipated costs associated with its management incentive program.   Selling, General and Administrative expenses consist of personnel costs, professional fees, sales commissions, sales training costs, industry trade show fees and expenses, product promotions and product literature costs, facilities costs and other sales, marketing and administrative costs, depreciation and amortization, and share-based compensation.  Personnel costs, excluding sales commissions and bonuses, represent approximately $1,571,000 or 18.8% of total Selling, General and Administrative expenses in the first quarter of 2013.

Net Interest Expense
We recorded financing and net interest expense of approximately $1,343,000 during the three months ended March 31, 2013, compared with approximately $462,000 of financing and net interest expense during the three months ended March 31, 2012.  The increase of approximately $881,000 is primarily due to the acceleration of debt discount related to the conversion of our Convertible Senior Secured Promissory Notes, which were issued during the last quarter of 2011.  The following table summarizes the interest charges for the three months ended March 31, 2013 and 2012:
Three Months Ended March 31,
2013
2012
Debt
Discount
Accrued Interest
Interest Expense
Total
Debt Discount
Accrued Interest
Interest Expense
Total
Convertible line of credit with related party
$ — $ — $ — $ — $ 11,423 $ 16,205 $ — $ 27,628
Converted debt related to acquisition
— — — — 80,353 10,521 — 90,874
Convertible Senior secured promissory notes
1,328,439 11,571 — 1,340,010 213,954 123,288 — 337,242
Deferred financing related to senior secured promissory notes
— — — — 4,747 — — 4,747
Other
— — 3,233 3,233 — — 1,796 1,796
$ 1,328,439 $ 11,571 $ 3,233 $ 1,343,243 $ 310,477 $ 150,014 $ 1,796 $ 462,287
Liquidity and Capital Resources
Revenue continues to increase quarter over quarter while management maintains tight controls over spending.  As of March 31, 2013, the Company had approximately $5,725,000 of cash and cash equivalents.  The Company reported total current assets of approximately $20,689,000 and total current liabilities of approximately $5,971,000 at March 31, 2013. The current ratio for the period decreased to 3.5 as compared to 3.6 as of December 31, 2012. Management believes that its anticipated cash from operating and financing activities and existing cash and cash equivalents will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next year.
Contractual Obligations
Contractual obligations associated with our ongoing business activities are expected to result in cash payments in future periods.  The table below summarizes the amounts and estimated timing of these future cash payments as of
March 31, 2013:

Less than
More than
Contractual Obligations
TOTAL
1 year
1-3 years
3-5 years
5 years
Capital lease obligations
$ 160,980 22,816 69,423 66,558 2,183
Operating lease obligations
375,820 243,630 132,190 - -
Royalty payments
550,000 - 100,000 100,000 350,000
$ 1,086,800 266,446 301,613 166,558 352,183
Discussion of cash flows
Net cash used in operations during the three months ended March 31, 2013, increased approximately $810,000 to $2,098,000 compared to $1,288,000 used in operating activities for the three months ended March 31, 2012, primarily attributable to increases in accounts receivable and inventory offset by increases in accrued compensation and accrued expenses.
Net cash used in investing activities during the three months ended March 31, 2013, increased approximately $27,000 to $74,000 compared to $47,000 used in investing activities for the three month period ended March 31, 2013.  The increase was due to increased purchases of property and equipment.
Net cash flows from financing activities during the three months ended March 31, 2013 increased approximately $898,000 to $1,142,000 compared to $244,000 during the three months ended March 31, 2012.  Cash flows from financing activities during the current quarter include approximately $925,000 received from the exercise of warrants, approximately $232,000 received from the exercise of stock options, and $15,000 in payments on capital lease obligations for equipment.
Due to the material amount of non-cash related items included in the Company results of operations, the Company has developed an Adjusted EBITDA metric which provides management with a clearer view of operational use of cash (see the table below).  The Adjusted EBITDA for the first quarter of 2013 was approximately $1,119,000 which is an improvement of approximately $805,000 as compared to the prior year quarter.  This improvement was the result of increased revenue and improved gross margins.
We use various numerical measures in investor conference calls, investor meetings and other forums which are or may be considered “Non-GAAP financial measures” under Regulation G.  We have provided below for your reference, supplemental financial disclosure for these measures, including the most directly comparable GAAP measure and an associated reconciliation.
The following table provides reconciliation of reported Net Loss on a GAAP basis to Adjusted EBITDA defined as Earnings before Interest, Taxes, Depreciation, Amortization and Share-Based Compensation:
Three Months Ended March 31,
2013
2012
Net Loss (Per GAAP)
$ (1,620,408 ) $ (1,093,652 )
Add back:
Income Taxes
50,275 -
Financing expense associated with beneficial conversion of note payable issued in conjunction with acquisition
- 80,353
Financing expense associated with beneficial conversion of Line of Credit with Related Party
- 11,423
Financing expense associated with beneficial conversion of Senior Secured Promissory Notes
1,328,439 218,701
Other interest expense, net
14,804 151,810
Depreciation Expense
98,751 110,388
Amortization Expense
262,596 333,977
Share Based Compensation
984,792 500,985
Earnings/(Loss) Before Interest, Taxes, Depreciation, Amortization and Share-Based Compensation
$ 1,119,249 $ 313,985
Critical Accounting Policies
In preparing our financial statements we follow accounting principles generally accepted in the United States, which require us to make certain estimates and apply judgments that affect our financial position and results of operations. We continually review our accounting policies and financial information disclosures. A summary of our significant accounting policies that require the use of estimates and judgments in preparing the financial statements was provided in our Annual Report on Form 10-K for the year ended December 31, 2012.  During the first three months of fiscal 2013, there were no material changes to the accounting policies and assumptions previously disclosed.
Recent Accounting Pronouncements
For the effect of recent accounting pronouncements, see Item 1 Financial Statements – Note 2.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.


There have been no significant changes from the disclosures presented in the Company’s Form 10-K for the year ended December 31, 2012.  For a discussion of the Company’s market risks, see Item 7A - “Quantitative and Qualitative Disclosures about Market Risk” of the Company’s Form 10-K for the year ended December 31, 2012.
Disclosure Controls and Procedures

As required by Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), we have carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. This evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Principal Financial Officer. Based upon that evaluation, our Chief Executive Officer and Principal Financial Officer concluded that our controls and procedures were effective as of the end of the period covered by this report.
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding disclosures.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the three months ended March 31, 2013, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Controls

We have confidence in our internal controls and procedures. Nevertheless, our management, including our Chief Executive Officer and Principal Financial Officer, does not expect that our disclosure procedures and controls or our internal controls will prevent all errors or intentional fraud. An internal control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of such internal controls are met. Further, the design of an internal control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all internal control systems, no evaluation of controls can provide absolute assurance that all our control issues and instances of fraud, if any, have been detected.
PART II – OTHER INFORMATION
None.

As of the date of this report, there have been no material changes to the risk factors included in Item 1A to our Annual Report on Form 10-K for the year ended December 31, 2012, except for the following:
Market Concentrations and Credit Risk
The Company’s principal market concentration of risk is related to its limited distribution channels.  Two customers accounted for approximately 75% of revenues for the quarter ended March 31, 2013, with one customer representing approximately 65% and another customer which represented approximately 10% of total revenue. The Company’s accounts receivable are derived from customers primarily located in the United States of America.  As of March 31, 2013 the same two customers accounted for approximately 76% of total accounts receivable.
During the three months ended March 31, 2013 the holders of the Company’s convertible debt converted their interest in the notes to shares of Common Stock.  The number of shares issued as a result of these transactions totaled approximately 5,272,000.  The Company also issued approximately 1,175,000 shares of Common Stock in final settlement of the earn-out liability connected with the 2011 acquisition of Surgical Biologics.  Additionally, the Company issued approximately 785,000 shares of common stock and received cash proceeds of approximately $925,000 for the exercise of warrants during the period.
None.
Not applicable.
None.
Item 6.
Exhibit
Number
Reference
Description
Lease dated January 25, 2013 by and between MiMedx Group, Inc., and HUB Properties GA, LLC.
10.2
MiMedx Group, Inc., 2013 Management Incentive Plan (MIP) and Operating Incentive Plan (OIP) (Filed as Exhibit 10.1 to the Company’s Form 8-K filed on March 12, 2013)
10.3
2013 Amendment to Assumed Stock Incentive Plan (Filed as Exhibit 10.2 to the Company’s Form 8-K filed on March 12, 2013)
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS
XBRL Instance Document
101.SCH
XBRL Taxonomy Extension Schema Document
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document

#
Filed herewith

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

May 10, 2013
By:
/s/ Michael J. Senken
Michael J. Senken
Chief Financial Officer
23
TABLE OF CONTENTS